Biopharmaceutical expert Edward Mathers joins NEAUS venture capital firm New Enterprise Associates has appointed Edward T Mathers as partner. Mathers will focus on healthcare investments in areas including biotechnology and specialty pharmaceuticals.
Mathers most recently served as executive vice president, corporate development and venture, at MedImmune. He was responsible for the company's licensing and business development activities and led the company's venture capital subsidiary MedImmune Ventures.
Mathers previously also worked as vice president, marketing and corporate licensing and acquisitions at Inhale Therapeutic Systems and spent 15 years at Glaxo Wellcome. He started his career at Ortho Pharmaceuticals Corporation, a division of Johnson & Johnson, as a researcher.
His current board positions are Kemia and Plexxikon.
'Ed's highly successful track record of strategic portfolio development across a range of technologies, disease targets and clinical stages adds significant depth to NEA's biopharmaceuticals investing practice, and we are thrilled to welcome him to the firm,' said NEA general partner Ryan Drant. 'His corporate development and venture capital investing experience brings a valuable perspective to our team, and we look forward to working with Ed as we continue to advance our portfolio of promising healthcare companies.'
NEA invests across all stages, from seed stage through IPO. The firm has approximately $8.5bn in committed capital.
It closed its latest fund, NEA 12, in summer 2006 on $2.5bn.
Copyright © 2008 AltAssets
Article is in the following categories:
Private Equity News» By News Type» People News
Private Equity News» By Region» North America» United States
Private Equity News» By News Type» People News
Private Equity News» By Region» North America» United States
